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Genomic DNA of a patient diagnosed with nonobstructive azoospermia and with the history of allogenic bone marrow
transplantation from his sister due to chronic myeloid leukemia was isolated from peripheral blood in order to screen Y
chromosomemicrodeletions.13shorttaggedsitesbelongingtoAZFa,b,andclociweredetectedwithmultiplexpolymerasechain
reaction technique. Bands were determined in ZFX/ZFY wells, whereas no bands were determined in wells of other STS regions.
DNA isolation was done from buccal mucosa smear to obtain genomic DNA from patient’s own cells and multiplex polymerase
chain reaction technique was performed again. Bands were seen in all wells of 13 STS regions. Y chromosome microdeletion was
not detected in the patient. In conclusion, genomic DNA isolation in patients undergoing BMT should be done from patients’ own
cells.
1.Introduction
Infertility aﬀects approximately 10–15% of couples, and
male factor infertility represents almost 50% of cases [1].
Among infertile men about 40–50% have azoospermia and
severe oligozoospermia. Genetic abnormalities may cause
infertility by aﬀecting sperm production or sperm trans-
port. These abnormalities are numerical (e.g., trisomy) and
structural (e.g., inversions or translocations) chromosomal
abnormalities, Y chromosome microdeletions, and gene
mutations (e.g., cystic ﬁbrosis). The frequencies of genetic
abnormalities vary between 10–15% in oligozoospermic and
azoospermic patients [2]. Because of this high prevalence, it
is important to investigate the chromosomal abnormalities
in these patients.
2.CaseReport
A healthy 27-year-old man with normal phenotype was
referred for the evaluation of infertility. In his physical
examination, right testis was 10cc, left testis was 8cc
with grade 1 varicocele. Vasa deferentia were palpable on
both sides. Consecutive two semen analyses of the patient
revealed azoospermia with normal ejaculate volume. His
serum FSH was 24.29 mIU/mL (1.6–12.4mIU/mL) and total
testosterone was 495ng/dL (260–1600ng/dL). The patient
with the diagnosis of nonobstructive azoospermia (NOA)
had a history of allogeneic bone marrow transplantation
(BMT) from his sister due to chronic myeloid leukemia
(CML). Karyotyping and Y chromosome microdeletion
analysis,whicharenecessaryfortheevaluationofNOA,were
done with peripheral blood leucocytes and buccal mucosa
samples because of the probable change in peripheral blood
leucocytes after allogeneic bone marrow transplantation.
There was no family history of infertility.
The patient, who had the diagnosis of CML with
positive Philadelphia (Ph) translocation in February 1999,
was treated with Hydroxyurea 500mg/day for two years. The
patient was conditioned with cyclophosphamide 60mg/kg
for two days and TBI with a total dose of 12Gy in 3
fractionated doses before BMT. In 2001, allogeneic BMT was
performed. After allogeneic BMT, the patient was treated2 Case Reports in Medicine
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Figure 1: Photos of 3% high-resolution agarose (mucinous agarose) gel electrophoresis of the three multiplex PCR amplicons from the
patient’s DNA (genomic DNA was isolated from venous blood cells) and control DNA. Band patterns of the control DNA: 1, 2, and 3, band
patterns of the patient’s DNA: 4, 5, and 6.
Figure 2: FISH analysis of interphase lymphocyte from the patient
with DNA probes of CepX/Y.
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Figure 3: Photos of 3 % high-resolution agarose (mucinous
agarose) gel electrophoresis of the three multiplex PCR amplicons
from the patient’s DNA (genomic DNA was isolated from buccal
mucosa) and control DNA. Band patterns of the control DNA: I, II,
and III, band patterns of the patient’s DNA: IV, V, and VI.
with 26mg methotrexate and 30gr IVIG. In cytogenetic
analysis performed on cultured cells from bone marrow
material before allogeneic BMT, no metaphases were exam-
ined. After BMT, cytogenetic analysis revealed 6 metaphases
examined bytrypsin GTGbanding, and4ofthemhad46,XX
chromosomal constitution.
3.MaterialsandMethods
Molecular cytogenetic and Y chromosome microdeletion
analysis was performed according to standard methods on
cultured cells from the patient’s peripheral blood. Genomic
DNAwasisolatedinaccordancewithkitprotocol(Highpure
PCR template preparation kit, Roche). In the laboratory,
kit which is used for determination of Y chromosome
microdeletion is certiﬁed with IVD (in vitro diagnostic).
13 STS (sequence tagged site) regions on Y chromosome
(ZFX/ZFY, SRY, AZFa: sY84, sY86, DFFRY, DBY, AZFb:
sY117, sY125, sY127, sY134, AZFc: DAZ gene sY254, sY255)
were analysed by using 3 diﬀerent polymerase chain reaction
(PCR) mixes (Genequality AZF MX, AB-Analitica). Mul-
tiplex PCR reaction was performed with isolated genomic
DNA samples in conformity with kit protocols. PCR prod-
ucts were subjected to 85V for electrophoresis during 2
hours and 30 minutes in 3% mucinous agarose gel.
4. Results
When the results of electrophoresis were investigated with
UV transilluminator, band patterns were detected only in
ZFX/ZFY wells of all 3 PCR mixes. There was no band
pattern in wells of other 12STS regions (Figure 1). This
situation was not compatible with phenotype of patient
and could occur due to allogenic BMT from his sister.
Therefore, chimerism analysis was done with FISH using
CepX/Y DNA probe (Vysis) in order to indicate chimerism
rate of sex chromosomes in cells of the peripheric circulatory
system of the patient. The CEP X/Y DNA probe is a
mixture of a SpectrumOrange labeled CEP X DNA probe
(Xp11.1-q11.1 Alpha Satellite DNA) and a SpectrumGreen
labeled CEP Y DNA probe speciﬁc for the alpha satellite
centromeric region of chromosome X and the satellite
III (Yq12) region of chromosome Y. Two orange signals
of Xp11.1-q11.1 Alpha Satellite DNA were found on the
interphase chromosome in 200 cells of peripheric circulatory
system of patient. It was determined that chimerism rate
was 100% XX (Figure 2). Towards this result, genomic
DNA was isolated from buccal mucosa smear in order to
obtain the patient’s own cells. Isolated genomic DNA was
evaluated with NanoDrop spectrophotometer (NanoDrop,
Thermo Scientiﬁc, USA) to detect the density of this sample.
1μL DNA of patient was deﬁned as 11.06ng and rateCase Reports in Medicine 3
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Figure 4: Electrophoretogram showing normal XY male sex chromosome constitution. Both the X- and Y- speciﬁc products of the AMXY
(X-Y amelogenin gene) are present with a normal ratio of 1:1. The XY male sex chromosome constitution is conﬁrmed by the occurrence
of the SRY product. In this example, the presence of two sex chromosomes is also further conﬁrmed by the normal heterozygous pattern of
both pseudoautosomal markers X22.
of A260/A280 was deﬁned as 1.42 which means that this
amount was enough for PCR. Then, PCR was performed
in accordance with kit protocol that was used previously.
PCR products were subjected to 85V for electrophoresis
during 2 hours and 30 minutes in 3% mucinous agarose
gel. Bands in wells of 3 diﬀerent mixes including 13STS
regions were detected with UV transilluminator. There were
band patterns in all wells, and Y chromosome microdeletion
was not detected in patient (Figure 3). Sex chromosomes
of patient were evaluated in terms of aneuploidy with
multiplex PCR in conformity with kit protocol (Aneufast-
QF PCR) used with Quantitative Fluorescent PCR (QF-
PCR) technique. The QF-PCR Kit contains six multiplex
marker sets of short tandem repeats (STRs) that can be
used for ampliﬁcation of selected microsatellites and the
Amelogenin-SRY. PCR products were subjected to capillary
electrophoresisinautomatizeddeviceofDNAstrandanalysis
(ABI-3100Avant).Fragmentanalysisshowedthatthepatient
had XY chromosomal constitution (Figure 4). After PCR,
AZF a, b, and c loci that were localized on Y chromosome
long arm and did not generate recombination with X
chromosome in meiosis were ampliﬁed (in the agarose gel,
bandpatternwaspositiveinwellsof10STSregionsspecialto
AZF loci). This also excludes the situation that patient could
have XX sex chromosome in the beginning.
5. Discussion
The incidence of Y chromosome microdeletions was report-
ed 10–15% and 5–10% in azoospermic and oligozoospermic
patients, respectively [3].
In the literature, there is only one report deﬁning a male
with the diagnosis of CML and 46,XX chromosomal con-
stitution [4]. That patient, like the present case, had bilateral
small testes, azoospermia, and hypergonadotropic hypog-
onadism. Cytogenetic and molecular analysis has demon-
strated that male XX is caused by at least three mecha-
nisms, abnormal Y-X interchange (90%), genes other than
testes-determining factor (TDF), and mosaicism [5]. It is
anticipated that malignant disease itself and adjuvant or
neoadjuvant regimens used for the treatment may result
in oligozoospermia and azoospermia [6]. Thachil et al.
reported that cancer itself has negative eﬀects on fertility
before application of any treatment modality [7]. It is also
reported that chemotherapeutic agents used in the treatment
of CML, like cyclosphosphamide, hydroxyurea, busulphan,
chlorambucil, and radiotherapy, have deleterious eﬀects on
germ cells which may result in azoospermia [8, 9].
The reason of azoospermia in the present case in unclear
whether it may be due to CML itself or the treatment regi-
mens used to cure the disease.
In another study, it is reported that the rate of recovery
of spermatogenesis was 17% in patients conditioned with
cyclophosphamide combined with total body irradiation
(TBI) before BMT. Recovery of spermatogenesis never
occurred before the fourth year after transplantation and
was observed up to 9 years. The incidence of azoospermia
in those patients was 70.3% [10] .T h er a t eo fg o n a d a l
dysfunction in patients treated with cyclophosphamide with
a cumulative dose of less than 400mg/kg was less than 10%
whereasthis rate was increased up to 30% in prepubertal and
68–95% in adult patients treated with a cumulative dose of
more than 400mg/kg cyclophosphamide [9, 10].
During TBI, the diﬀused testicular dose is estimated to
be 1-2% of the total dose applied. Direct irradiation (0.15–
0.35Gy) causes oligozoospermia; doses between 0.35Gy
and 0.5Gy cause reversible azoospermia. Doses of 1.2Gy
are associated with a reduced risk of recovery of sper-
matogenesis. Time to recovery is also likely to depend on4 Case Reports in Medicine
the dose [8]. Cumulative doses of fractionated radiotherapy
of>2.5Gygenerallyresultinprolongedandlikelypermanent
azoospermia. Radiation doses to the germinal epithelium of
the testis given in 3- to 7-week fractionated courses cause
more gonadal damage than single doses. An irreversible
damage of the spermatogenesis will begin at a cumulative
dose of >2.5Gy when the radiation is fractionated [11].
The present case was conditioned with cyclophosphamide
60mg/kg for two days and TBI with a total dose of 12Gy in 3
fractionated doses before BMT. Recovery of spermatogenesis
never occurred during the 8-year followup after BMT.
Pretreatment sperm cryopreservation, although not
applied in this case, should be oﬀered to young, male cancer
patientstopreventinfertilityduetothetherapeuticregimens
which causes oligozoospermia or azoospermia.
To the best of our knowledge, the study does not provide
a new information methodologically but from the point of
clinical view this is the ﬁrst NOA case with the diagnosis
of CML and 46,XX chromosomal constitution due to
allogeneic BMT from his sister. In conclusion, genomic DNA
investigation in patients undergoing BMT should be done
withpatients’owncells(buccalmucosa,tissuebiopsy,etc.)to
obtain accurate results about the chromosomal constitutions
of these patients.
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